title: A cost analysis on the pattern of asthma prescribing in the UK.
abstract: There is a need to establish the proportion of adult asthmatics at each step of the recommended asthma management guidelines, the cost of their prescribed treatment, and a revised cost of treatment assuming patients who were suboptimally controlled were moved up a step. Actual prescription and cost figures and a theoretical projection of an ideal scenario was calculated from a sample of general practices in Great Britain from the Doctors Independent Network. They comprised 102 nationally distributed practices and 17,206 adult patients with a diagnosis of, and prescription related to, asthma recorded between October 1993 and March 1994. Ninety-one per cent of patients received treatment within a recognized step of the guidelines. Of these, 80% were at steps 1 and 2. Employing excess inhaled beta-agonist use as a proxy for control of asthma, between 55% and 69% of patients at Steps 1-3 should receive treatment at a higher step. This could lead to an increased expenditure of up to Pound Sterling 4.66 per adult patient per month. This would imply a rise in the annual UK cost of antiasthma prescriptions for adults from Pound Sterling 388m to a possible Pound Sterling 533m. The United Kingdom Government audit commission has suggested that current expenditure on asthma treatment appears to be insufficient. Using an entirely different approach this study has confirmed that a significant increase in asthma prescribing costs is likely to be needed if optimal control of asthma is to be achieved.
authors.affiliation: University of Dundee, Tayside Centre for General Practice, UK.
authors.forename: R G
authors.initials: RG
authors.lastname: Neville
authors.forename: M G
authors.initials: MG
authors.lastname: Pearson
authors.forename: N
authors.initials: N
authors.lastname: Richards
authors.forename: J
authors.initials: J
authors.lastname: Patience
authors.forename: S
authors.initials: S
authors.lastname: Sondhi
authors.forename: B
authors.initials: B
authors.lastname: Wagstaff
authors.forename: N
authors.initials: N
authors.lastname: Wells
mesh_terms: D000293:Adolescent; D000318:Adrenergic beta-Agonists / Q000191:economics / Q000627:therapeutic use; D000328:Adult; D018927:Anti-Asthmatic Agents / Q000191:economics* / Q000627:therapeutic use; D001249:Asthma / Q000188:drug therapy / Q000191:economics*; D001993:Bronchodilator Agents / Q000191:economics / Q000627:therapeutic use; D003365:Costs and Cost Analysis; D016527:Drug Costs; D004359:Drug Therapy, Combination; D006801:Humans; D011306:Prescription Fees / Q000706:statistics & numerical data; D012189:Retrospective Studies; D013256:Steroids / Q000191:economics / Q000627:therapeutic use; D013806:Theophylline / Q000191:economics / Q000627:therapeutic use; D006113:United Kingdom
chemical_list: D000318:Adrenergic beta-Agonists; D018927:Anti-Asthmatic Agents; D001993:Bronchodilator Agents; D013256:Steroids; D013806:Theophylline